7.66
0.15 (2.00%)
| Penutupan Terdahulu | 7.51 |
| Buka | 7.54 |
| Jumlah Dagangan | 458,337 |
| Purata Dagangan (3B) | 1,934,585 |
| Modal Pasaran | 494,605,952 |
| Harga / Jualan (P/S) | 563.62 |
| Harga / Buku (P/B) | 1.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -1.97 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.76% |
| Nisbah Semasa (MRQ) | 7.48 |
| Aliran Tunai Operasi (OCF TTM) | -53.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -32.40 M |
| Pulangan Atas Aset (ROA TTM) | -57.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -102.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Immuneering Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 24.12% |
| % Dimiliki oleh Institusi | 12.55% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Burkehill Global Management, Lp | 30 Sep 2025 | 300,000 |
| Iridian Asset Management Llc/Ct | 30 Sep 2025 | 275,086 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (Oppenheimer, 291.65%) | Beli |
| Median | 15.00 (95.82%) | |
| Rendah | 11.00 (HC Wainwright & Co., 43.60%) | Beli |
| 11.00 (Needham, 43.60%) | Beli | |
| Purata | 17.40 (127.15%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 7.24 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Nov 2025 | 20.00 (161.10%) | Beli | 6.45 |
| 26 Sep 2025 | 20.00 (161.10%) | Beli | 8.08 | |
| Leerink Partners | 31 Oct 2025 | 15.00 (95.82%) | Beli | 6.87 |
| HC Wainwright & Co. | 30 Sep 2025 | 11.00 (43.60%) | Beli | 7.00 |
| Oppenheimer | 25 Sep 2025 | 30.00 (291.64%) | Beli | 8.00 |
| Needham | 15 Sep 2025 | 11.00 (43.60%) | Beli | 7.86 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |